Amarin Corporation plc filings document operating results and material events for a pharmaceutical company commercializing icosapent ethyl cardiovascular therapy. Form 8-K reports furnish quarterly and annual financial results, preliminary financial highlights, operational priorities, U.S. and international commercialization updates, license and supply arrangements, cost-optimization actions, and scientific publication activity related to VASCEPA/VAZKEPA.
Definitive proxy and governance filings cover annual meeting matters, executive compensation, equity awards under stock incentive plans, board composition, director compensation policies, and leadership appointments.
Amarin Corporation plc reports that at its Annual General Meeting, shareholders re-elected all director nominees and approved the non-binding Say-on-Pay proposal, but several key capital and governance measures failed. Proposals to authorize the Board to issue shares up to a nominal £37,750,000, to increase the 2020 Stock Incentive Plan reserve by 15,000,000 Ordinary Shares, to disapply UK statutory pre-emption rights on up to £20,970,000 of share capital, and to permit electronic delivery of meeting materials were not approved. The Board states that, without these approvals, its ability to grant equity incentives to employees and directors is highly limited, so it expects most future annual incentive compensation to be paid in cash, which will affect the company’s total cash position. Amarin also expects to continue incurring printing and mailing costs for paper proxy materials. Turnout was substantial, with 295,122,317 Ordinary Shares, about 70% of the 419,458,656 shares entitled to vote as of the record date, present in person or by proxy.
Amarin Corporation reported a Q1 2026 net loss of $10.5 million, improving from $15.7 million a year earlier, as revenue edged up and operating costs fell. Total revenue reached $45.1 million, including $43.3 million of product sales and $1.8 million of licensing and royalty income.
Gross margin declined as cost of goods sold rose to $27.4 million, but selling, general and administrative expenses dropped sharply to $21.1 million, partly reflecting restructuring. The company recorded $3.3 million of restructuring expense and $3.1 million of litigation settlements. Amarin ended the quarter with $307.8 million in cash and short‑term investments, total assets of $645.8 million, and no debt, while generating $6.4 million of cash from operating activities.
Amarin Corporation reported Q1 2026 total net revenue of $45.1 million, up 7% from Q1 2025, driven by stable U.S. VASCEPA sales, higher rest-of-world product revenue, and an 84% increase in licensing and royalty revenue.
Total operating expenses fell 31% to $29.1 million, mainly from the June 2025 Global Restructuring and lower selling, general and administrative costs, which declined 42%. Operating loss narrowed to $11.3 million, and net loss improved to $10.5 million, or $(0.03) per ordinary share.
The company generated positive cash flow, with cash and investments rising to $307.8 million as of March 31, 2026, and remained debt free. On a non-GAAP basis, net loss was reduced to $1.8 million, reflecting add-backs for stock-based compensation, restructuring and a litigation settlement.
Amarin director Patrice Eadon Bonfiglio reported routine equity compensation activity involving American Depositary Shares (ADSs). On April 18, 2026, previously granted restricted stock units vested, resulting in the acquisition of 838 ADSs through a derivative exercise. In connection with this vesting, the company withheld 403 ADSs at a value of $14.98 per ADS to cover tax obligations, which the filing notes is not a market sale under Rule 16b-3. After these transactions, Bonfiglio directly owns 836 ADSs. Footnotes explain that one ADS represents twenty ordinary shares following an ADS ratio change and that the RSUs were granted under Amarin’s 2020 Stock Incentive Plan, vesting in three equal annual installments.
Amarin Corporation director Paul Cohen reported routine equity compensation activity involving American Depositary Shares (ADS). On April 18, 2026, 838 ADS were acquired at $0.00 per share through the exercise of Restricted Stock Units, reflecting an equity award vesting. On the same date, 403 ADS at $14.98 per share were withheld by Amarin to cover tax liabilities tied to this vesting, which a footnote clarifies is not a market sale of securities under Rule 16b‑3. Following these transactions, Cohen directly held 1,239 ADS. Footnotes note a prior ADS ratio change, with each ADS now representing twenty ordinary shares and each RSU representing a contingent right to receive twenty ordinary shares or cash.
Amarin director Louis Sterling III reported routine equity compensation activity involving American Depositary Shares (ADSs). On April 18, he exercised 838 Restricted Stock Units (RSUs), receiving 838 ADSs at a stated price of $0.00 per ADS.
On the same date, 403 ADSs were withheld by Amarin to cover tax liabilities related to the vesting, at a value of $14.98 per ADS, which the company notes is not a market sale of securities. After these transactions, Sterling’s direct holdings increased to 4,452 ADSs.
Footnotes explain that Amarin previously implemented an ADS ratio change so that one ADS represents twenty ordinary shares, and that the RSUs were part of a 2,514-unit grant made on April 18, 2024, vesting in three equal annual installments under the 2020 Stock Incentive Plan.
Amarin director Odysseas D. Kostas reported routine equity compensation activity involving American Depositary Shares (ADS). On April 18, 2026, he exercised 838 Restricted Stock Units (RSUs), acquiring 838 ADS at a stated price of $0.00 per ADS.
In connection with this vesting, 403 ADS were withheld by Amarin to cover related tax liabilities, as described in the filing as a tax-withholding disposition under Rule 16b-3, not a market sale. After these transactions, Kostas directly held 1,239 ADS.
The RSUs stem from a grant of 2,514 RSUs made on April 18, 2024 under Amarin’s 2020 Stock Incentive Plan, vesting in three equal installments on April 18, 2025, 2026, and 2027. Each RSU represents a contingent right to receive twenty ordinary shares or cash, and all reported amounts reflect a prior ADS ratio change.
Amarin Corporation director Diane E. Sullivan reported compensation-related share activity involving American Depositary Shares (ADS) on April 18, 2026. She exercised 838 Restricted Stock Units (RSUs) into 838 ADS at a stated price of $0.00 per ADS, reflecting a scheduled vesting under the company’s 2020 Stock Incentive Plan. To cover tax liabilities from this vesting, 403 ADS were withheld by Amarin at $14.98 per ADS, which the company notes was not a market sale. Following these transactions, Sullivan directly holds 1,239 ADS. Footnotes explain that each RSU represents a contingent right to receive twenty ordinary shares or cash and that the reported amounts reflect a prior ADS ratio change.
Amarin Corporation director Keith Horn reported routine equity compensation activity involving American Depositary Shares (ADSs). On April 18, 2026, 838 ADSs were issued upon the exercise of 838 Restricted Stock Units (RSUs), reflecting an earlier grant under Amarin’s 2020 Stock Incentive Plan. On the same date, 403 ADSs were withheld by Amarin to cover tax liabilities tied to this vesting, at an indicated value of $14.98 per ADS, which the company clarifies is not a market sale under Rule 16b-3. After these transactions, Horn directly owned 1,239 ADSs. Footnotes note that one ADS currently represents twenty ordinary shares following a prior ADS ratio change and that the original RSU grant totaled 2,514 units vesting in three equal annual installments.
Amarin Corporation director Oliver O’Connor reported routine equity compensation activity involving American Depositary Shares (ADSs). On April 18, he acquired 838 ADSs through the vesting and conversion of Restricted Stock Units, while 438 ADSs were withheld by the company to cover tax obligations.
After these transactions, he directly held 1,239 ADSs. A prior grant on April 18, 2024 covered 2,514 RSUs vesting in three equal installments on April 18, 2025, 2026 and 2027. Each RSU represents a contingent right to receive one ADS, and each ADS currently represents twenty ordinary shares after an ADS ratio change.